Microangiopathic Hemolytic Anemia

Microangiopathic Hemolytic Anemia is a condition where small blood vessels become damaged, causing red blood cells to break apart as they pass through. This affects the circulatory system and leads to a shortage of healthy red blood cells, which are important for carrying oxygen throughout the body. The damage to blood vessels can cause symptoms like fatigue, paleness, and sometimes bleeding or bruising. It often occurs alongside other serious illnesses that affect blood flow or cause inflammation. The main health impact is due to the destruction of red blood cells and the resulting anemia, which can make it harder for the body to get enough oxygen.

Microangiopathic Hemolytic Anemia (MAHA) is a form of hemolytic anemia characterized by the mechanical destruction of red blood cells within the microvasculature. It results from endothelial injury or microvascular pathology causing fibrin deposition and formation of microthrombi, which shear passing erythrocytes, producing schistocytes on peripheral smear. Common causes include thrombotic microangiopathies such as thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), as well as malignant hypertension and disseminated intravascular coagulation (DIC). MAHA is clinically significant due to its association with organ ischemia, thrombocytopenia, and potential for rapid clinical deterioration. The hallmark is the presence of fragmented red cells and elevated markers of hemolysis, reflecting ongoing microvascular injury and red cell destruction.